Dendritic Cells in Cancer Immunotherapy
Authors:
- Kristen J RadfordKRKristen J Radford
- Cornelis MeliefCMCornelis Melief
- Derek N J HartDHDerek N J Hart
- 1 January 2008
- book chapter
- Published by Elsevier
- Vol. 99, 363-407
Abstract
No abstract availableKeywords
This publication has 238 references indexed in Scilit:
- Transforming-growth factor β1 Leu10Pro polymorphism and breast cancer morbidityEuropean Journal of Cancer, 2007
- Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapyProceedings of the National Academy of Sciences, 2006
- Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies?Cancer and Metastasis Reviews, 2006
- Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?British Journal of Cancer, 2006
- Dendritic Cell-Based Tumor Vaccines and Antigen Presentation AttenuatorsMolecular Therapy, 2006
- Adoptive immunotherapy for cancer: building on successNature Reviews Immunology, 2006
- Dendritic Cells and Tumor Microenvironment: A Dangerous LiaisonImmunological Investigations, 2006
- Immunosuppressive agents mediate reduced allostimulatory properties of myeloid-derived dendritic cells despite induction of divergent molecular phenotypesMolecular Immunology, 2005
- A listing of human tumor antigens recognized by T cells: March 2004 updateCancer Immunology, Immunotherapy, 2004
- Extended neoadjuvant chemotherapy in locally advanced breast cancer combined with GM-CSFEuropean Journal of Cancer, 2003